CytoDyn Inc. (OTCMKTS:CYDY) Sees Large Growth in Short Interest

CytoDyn Inc. (OTCMKTS:CYDY) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 16,577,600 shares, a growth of 25.8% from the October 15th total of 13,179,400 shares. Based on an average daily volume of 6,265,900 shares, the days-to-cover ratio is presently 2.6 days.

CytoDyn Price Performance

Shares of CYDY stock remained flat at $0.12 during trading hours on Friday. The stock had a trading volume of 2,795,684 shares, compared to its average volume of 2,584,065. The stock has a market capitalization of $149.98 million, a PE ratio of -6.06 and a beta of 0.17. CytoDyn has a 1 year low of $0.11 and a 1 year high of $0.42. The business has a 50 day simple moving average of $0.14 and a 200-day simple moving average of $0.15.

CytoDyn (OTCMKTS:CYDY) last released its quarterly earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 EPS for the quarter.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.